Cantor Fitzgerald initiated coverage of Pharvaris (PHVS) with an Overweight rating and $28 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris: Buy Rating Backed by Clinical Progress, Market Potential, and Strong Financial Position
- Pharvaris Faces Uncertainty Amid Competitive HAE Market and Pivotal Trial Challenges
- Pharvaris’s Strategic Advancements and Strong Financial Position Drive Buy Rating
- Pharvaris Reports 2024 Financial Results and Business Progress
- Pharvaris Positioned for Growth with Successful Trial and Strong Financials, Analyst Projects Significant Market Expansion